Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 19, 2019 - Issue 10: Biosimilars
Submit an article Journal homepage
7,650
Views
11
CrossRef citations to date
0
Altmetric
Review

Rituximab biosimilars for lymphoma in Europe

Wojciech JurczakOncology Centre, Maria Skłodowska-Curie Institute, Kraków, PolandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1879-8084View further author information
ORCID Icon,
Monika Długosz DaneckaOncology Centre, Maria Skłodowska-Curie Institute, Kraków, PolandView further author information
&
Christian BuskeComprehensive Cancer Center Ulm, Institute for Experimental Tumor Research, University Hospital Ulm, Ulm, Baden-Württemberg, GermanyView further author information
Pages 1045-1056 | Received 16 May 2019, Accepted 04 Sep 2019, Published online: 30 Sep 2019

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Kanjaksha Ghosh & Kinjalka Ghosh. (2022) Monoclonal antibodies used for the management of hemataological disorders. Expert Review of Hematology 15:5, pages 443-455.
Read now
Wojciech Jurczak & Monika Długosz-Danecka. (2020) Rituximab biosimilars in clinical practice. Leukemia & Lymphoma 61:7, pages 1523-1524.
Read now
Magdalena Olszewska-Szopa, Agnieszka Ożańska, Tomasz Ożański, Justyna Rybka & Tomasz Wróbel. The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience. Leukemia & Lymphoma 0:0, pages 1-7.
Read now

Articles from other publishers (8)

Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu & Maya A. Eicher. (2023) Therapeutic Antibodies in Medicine. Molecules 28:18, pages 6438.
Crossref
Jing Zeng, Yalin Chen, Tingting Zhang, Jinjing Wang, Yan Yang & Yi Fang. (2023) Effect of a CrossMab cotargeting CD20 and HLA-DR in non-Hodgkin lymphoma. Oncologie 0:0.
Crossref
Shuting Ye, Weiwei Ying, Yi Lin, Zhengjun Hou & Meiyun Su. (2022) LncRNA OR2A1‐AS1 index predicts survival in germinal center‐like diffuse large B‐cell lymphoma . Journal of Clinical Laboratory Analysis 36:10.
Crossref
Jeff P Sharman, Carol F Kirchhoff & Robert M Rifkin. (2022) Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study. Future Oncology 18:12, pages 1499-1510.
Crossref
Fei Peng, Jingwen Li, Shidai Mu, Li Cai, Fengjuan Fan, You Qin, Lisha Ai & Yu Hu. (2021) Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival. The Breast 57, pages 49-61.
Crossref
Myrna Candelaria & Alfonso Dueñas-Gonzalez. (2021) Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Therapeutic Advances in Hematology 12, pages 204062072198957.
Crossref
Thomas DelateMargaret L. HansenAmarylis C. GutierrezKim N. Le. (2020) Indications for Rituximab Use in an Integrated Health Care Delivery System. Journal of Managed Care & Specialty Pharmacy 26:7, pages 832-838.
Crossref
Burkhard Otremba, Jens Borchardt, Andra Kuske, Maike Hollnagel-Schmitz & Florian O Losch. (2020) Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany. Future Oncology 16:15, pages 1001-1012.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.